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A case of a 7-year-old male with epilepsy who developed non-convulsive status epilepticus (NCSE) with electroclinical fea-
tures consistent with those of atypical absence seizures after adjunctive antiepileptic therapy of tiagabine (TGB) is reported.
The patient had frequent generalised and rare partial seizures with generalised epileptic discharges on prior electroencephalo-
gram (EEG) recordings. NCSE was developed when rapid dosage increase and high dose of TGB was given. This case em-
phasises the need for close monitoring of children with epilepsy taking TGB for exacerbation of seizures or development
of NCSE.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Tiagabine (TGB) is a GABA-uptake inhibitor in-
creasing the effect of GABA and may exacerbate
some types of seizures, particularly absences and
myoclonic seizures1. Recently, a number of cases of
non-convulsive status epilepticus (NCSE) associated
with TGB have been reported in patients with chronic
partial epilepsy and in one patient with idiopathic
generalised epilepsy2–11. TGB-induced NCSE has
been described only in adults and paediatric patients
over the age of 12 years. In this report, a child with
long-standing NCSE provoked by TGB is reported. To
our knowledge, this is the first report of NCSE associ-
ated with TGB in children under the age of 12 years.
CASE REPORT
A 7-year-old boy with epilepsy was admitted to our
hospital in a confused state. He is the first child of
the family and the product of a full-term uncompli-
cated gestation, labour and delivery. Family history
was unremarkable for neurological disorders. The
child had a history of infantile spasms and delay in
motor and cognitive development. Since the age of
2 years, he suffered from frequent myoclonic seizures
and rare atypical absences, tonic, atonic and simple
partial seizures of unknown aetiology. The interic-
tal electroencephalogram (EEG) showed generalised
sharp waves and/or 2–2.5 Hz spike-wave discharges
(SWDs) and the brain magnetic resonance imaging
was normal. Before the episode described in the
present report, the child had never experienced NCSE
or any other type of status epilepticus (SE).
The patient had tried most other antiepileptic drugs
without achieving satisfactory control and TGB in
addition to sodium valproate was administered. Dur-
ing a 7-month follow-up period, the add-on treatment
with TGB in a dose of 0.25–0.40 mg/kg/day reduced
the frequency of myoclonic seizures, while there was
some increase in the number of atypical absences. As
the response to treatment with sodium valproate and
TGB was incomplete, TGB was administered in in-
creasing dosages. Dosage was escalated every 6 days
by 0.2 mg/kg/day to a maximum of 1 mg/kg/day.
Two days after reaching the maximum dose, the
boy developed episodes of confusion lasting up to
90 minutes, and finally, 7 days after the onset of these
episodes, he manifested continuous blank staring
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Fig. 1: EEG recording during NCSE showing runs of irregular generalised, high-amplitude, 3–3.5 Hz SWDs. Calibration:
1 second, 50µV.
and unresponsiveness and was admitted to our hos-
pital. The ictal EEG showed long runs of irregular
generalised 3–3.5 Hz SWDs, which did not resem-
ble the patient’s usual EEG findings, consistent
with a diagnosis of absence status epilepticus (ASE)
(Fig. 1). The trough blood level of sodium valproate
was 100 mg/l (therapeutic range 50–100 mg/l), which
was almost unchanged as compared with the con-
centration measured 12 days earlier. Immediate dis-
continuation of TGB and intravenous treatment with
midazolam was followed by complete and sustained
electroclinical remission, indicating a causative role
of TGB for NCSE. The patient’s EEG recorded 2
days after admission to our hospital did not show
any paroxysmal abnormalities. In a follow-up pe-
riod of 3 years, he has been treated with a combi-
nation of sodium valproate and clobazam and the
seizure frequency remained unchanged, no NCSE
re-occurred and the EEG recordings showed the usual
findings.
DISCUSSION
TGB is currently recommended as add-on therapy
in adults and children above 12 years with par-
tial epilepsy not satisfactorily controlled with other
antiepileptic drugs. Efficacy in other types of epilepsy
requires further study and very few studies on the
efficacy and safety of TGB in childhood have been
published12. In symptomatic generalised epilepsies
or epilepsies associated with diffuse encephalopathy
syndrome, the patients have often multiple seizure
types that may respond in different ways to TGB1, 12.
Although a number of cases of NCSE associated with
TGB have been reported2–11, precise evidence for this
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association from epidemiological studies is lacking13.
It was also suggested that TGB-related stupor is most
probably not epileptic in nature, as EEG tracings have
showed diffuse slowing or a pattern different from
diffuse synchronous bursts of spike and wave13.
Our case had severe epilepsy and therefore NCSE
might have occurred spontaneously; however, the
temporal relationship between the appearance of
NCSE and the high and rapid increase of dose of TGB
together with the rapid recovery when TGB therapy
was stopped provides strong evidence that NCSE was
probably induced from TGB therapy. As ictal EEG
recordings in previous reported cases with NCSE
associated with TGB were not usually performed
during the episodes of NCSE, it was difficult to dif-
ferentiate between complex partial seizure activity
or long-standing atypical absence activity. In this re-
port, the patient developed NCSE with electroclinical
features consistent with those of atypical ASE.
There are insufficient data at present to identify risk
factors for developing NCSE associated with TGB.
Although it was suggested that most of the affected
patients had pre-existing generalised SWDs, precipi-
tation of apparent NCSE has also been described with-
out a history of such discharges10. In our patient, the
majority of seizures were generalised and only gener-
alised epileptic discharges were recorded on previous
EEG. In contrast to the observations from clinical tri-
als where an episode of NCSE was more common in
patients with known prior SE, only few of the reported
cases had a history of former SE10, 13. Confirming this
pattern, our patient had never experienced SE before.
Case reports of NCSE under TGB suggested a
specific role of dose levels, since in these patients
symptoms occurred mostly at a high dose of TGB.
However, cases of NCSE in patients receiving a low
dose of TGB have been reported, suggesting an indi-
vidual risk threshold of unknown aetiology10. More-
over, it was suggested that rapid dosage increase of
TGB might have contributed in developing NCSE13.
In our patient, NCSE developed when high dose
and rapid dosage increase of TGB was given. Up to
now, there is no evidence that a specific interaction
between TGB and other antiepileptic drugs could pro-
voke or facilitate NCSE9, 10. Our patient developed
NCSE while receiving a combination of TGB and
sodium valproate, which is a non-enzyme inducing
antiepilepic drug and might have increased the total
and/or free concentration of TGB in serum.
The findings in our case suggest that clinicians
should beware of the possible occurrence of NCSE
in children with epilepsy under the anticonvulsant
TGB, especially in those with generalised or multiple
seizures, generalised EEG abnormalities, high dose
and/or rapid dosage increase of TGB.
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